Filtros : "2018" "Bayer" Removidos: "Bioquímica" "PEDIATRIA" "Financiamento ANP" Limpar

Filtros



Refine with date range


  • Source: Journal of the american college of cardiology. Unidade: FM

    Subjects: ANTI-INFLAMATÓRIOS, DOENÇAS CARDIOVASCULARES, DIABETES MELLITUS

    Acesso à fonteDOIHow to cite
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
    • ABNT

      EVERETT, Brendan M. et al. Anti-Inflammatory Therapy With Canakinumab for the Prevention and Management of Diabetes. Journal of the american college of cardiology, v. 71, n. 21, p. 2392-2401, 2018Tradução . . Disponível em: https://doi.org/10.1016/j.jacc.2018.03.002. Acesso em: 15 nov. 2024.
    • APA

      Everett, B. M., Nicolau, J. C., DONATH, M. Y., PRADHAN, A. D., THUREN, T., PAIS, P., et al. (2018). Anti-Inflammatory Therapy With Canakinumab for the Prevention and Management of Diabetes. Journal of the american college of cardiology, 71( 21), 2392-2401. doi:10.1016/j.jacc.2018.03.002
    • NLM

      Everett BM, Nicolau JC, DONATH MY, PRADHAN AD, THUREN T, PAIS P, GLYNN RJ, LIBBY P, RIDKER PM. Anti-Inflammatory Therapy With Canakinumab for the Prevention and Management of Diabetes [Internet]. Journal of the american college of cardiology. 2018 ; 71( 21): 2392-2401.[citado 2024 nov. 15 ] Available from: https://doi.org/10.1016/j.jacc.2018.03.002
    • Vancouver

      Everett BM, Nicolau JC, DONATH MY, PRADHAN AD, THUREN T, PAIS P, GLYNN RJ, LIBBY P, RIDKER PM. Anti-Inflammatory Therapy With Canakinumab for the Prevention and Management of Diabetes [Internet]. Journal of the american college of cardiology. 2018 ; 71( 21): 2392-2401.[citado 2024 nov. 15 ] Available from: https://doi.org/10.1016/j.jacc.2018.03.002
  • Source: European respiratory journal. Unidade: FM

    Subjects: ESQUISTOSSOMOSE, HIPERTENSÃO PULMONAR, SOBREVIDA

    Acesso à fonteDOIHow to cite
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
    • ABNT

      FERNANDES, Caio Julio Cesar et al. Survival of patients with schistosomiasis-associated pulmonary arterial hypertension in the modern management era. European respiratory journal, v. 51, n. 6, 2018Tradução . . Disponível em: https://doi.org/10.1183/13993003.00307-2018. Acesso em: 15 nov. 2024.
    • APA

      Fernandes, C. J. C., Souza, R., PILOTO, B., CASTRO, M., OLEAS, F. G., ALVES JR., J. L., et al. (2018). Survival of patients with schistosomiasis-associated pulmonary arterial hypertension in the modern management era. European respiratory journal, 51( 6). doi:10.1183/13993003.00307-2018
    • NLM

      Fernandes CJC, Souza R, PILOTO B, CASTRO M, OLEAS FG, ALVES JR. JL, PRADA LFL, JARDIM C. Survival of patients with schistosomiasis-associated pulmonary arterial hypertension in the modern management era [Internet]. European respiratory journal. 2018 ; 51( 6):[citado 2024 nov. 15 ] Available from: https://doi.org/10.1183/13993003.00307-2018
    • Vancouver

      Fernandes CJC, Souza R, PILOTO B, CASTRO M, OLEAS FG, ALVES JR. JL, PRADA LFL, JARDIM C. Survival of patients with schistosomiasis-associated pulmonary arterial hypertension in the modern management era [Internet]. European respiratory journal. 2018 ; 51( 6):[citado 2024 nov. 15 ] Available from: https://doi.org/10.1183/13993003.00307-2018
  • Source: Journal of the american college of cardiology. Unidade: FM

    Subjects: ANTICOAGULANTES, FIBRILAÇÃO ATRIAL, ACIDENTE VASCULAR CEREBRAL, AMÉRICA LATINA

    Acesso à fonteDOIHow to cite
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
    • ABNT

      CORBALAN, Ramon e NICOLAU, Jose Carlos. Edoxaban versus warfarin in Latin American Patients with atrial fibrillation the ENGAGE AF-TIMI 48 trial. Journal of the american college of cardiology, v. 72, n. 13, p. 1466-1475, 2018Tradução . . Disponível em: https://doi.org/10.1016/j.jacc.2018.07.037. Acesso em: 15 nov. 2024.
    • APA

      Corbalan, R., & Nicolau, J. C. (2018). Edoxaban versus warfarin in Latin American Patients with atrial fibrillation the ENGAGE AF-TIMI 48 trial. Journal of the american college of cardiology, 72( 13), 1466-1475. doi:10.1016/j.jacc.2018.07.037
    • NLM

      Corbalan R, Nicolau JC. Edoxaban versus warfarin in Latin American Patients with atrial fibrillation the ENGAGE AF-TIMI 48 trial [Internet]. Journal of the american college of cardiology. 2018 ; 72( 13): 1466-1475.[citado 2024 nov. 15 ] Available from: https://doi.org/10.1016/j.jacc.2018.07.037
    • Vancouver

      Corbalan R, Nicolau JC. Edoxaban versus warfarin in Latin American Patients with atrial fibrillation the ENGAGE AF-TIMI 48 trial [Internet]. Journal of the american college of cardiology. 2018 ; 72( 13): 1466-1475.[citado 2024 nov. 15 ] Available from: https://doi.org/10.1016/j.jacc.2018.07.037
  • Source: Journal of the american college of cardiology. Unidade: FM

    Subjects: HIPERCOLESTEROLEMIA, DOENÇAS CARDIOVASCULARES, COLESTEROL, CUSTOS DOS CUIDADOS DE SAÚDE

    Acesso à fonteDOIHow to cite
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
    • ABNT

      STURM, Amy C. e SANTOS, Raul D. Clinical Genetic Testing for Familial Hypercholesterolemia. Journal of the american college of cardiology, v. 72, n. 6, p. 662-680, 2018Tradução . . Disponível em: https://doi.org/10.1016/j.jacc.2018.05.044. Acesso em: 15 nov. 2024.
    • APA

      Sturm, A. C., & Santos, R. D. (2018). Clinical Genetic Testing for Familial Hypercholesterolemia. Journal of the american college of cardiology, 72( 6), 662-680. doi:10.1016/j.jacc.2018.05.044
    • NLM

      Sturm AC, Santos RD. Clinical Genetic Testing for Familial Hypercholesterolemia [Internet]. Journal of the american college of cardiology. 2018 ; 72( 6): 662-680.[citado 2024 nov. 15 ] Available from: https://doi.org/10.1016/j.jacc.2018.05.044
    • Vancouver

      Sturm AC, Santos RD. Clinical Genetic Testing for Familial Hypercholesterolemia [Internet]. Journal of the american college of cardiology. 2018 ; 72( 6): 662-680.[citado 2024 nov. 15 ] Available from: https://doi.org/10.1016/j.jacc.2018.05.044
  • Source: Journal of heart and lung transplantation. Unidade: FM

    Subjects: RIM, HIPERTENSÃO PULMONAR, PROGNÓSTICO

    Acesso à fonteDOIHow to cite
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
    • ABNT

      ALVES- JR., Jose Leonidas e SOUZA, Rogerio. Prognostic relevance of appropriate renal function evaluation in pulmonary arterial hypertension. Journal of heart and lung transplantation, v. 37, n. 6, p. 692-693, 2018Tradução . . Disponível em: https://doi.org/10.1016/j.healun.2018.02.005. Acesso em: 15 nov. 2024.
    • APA

      Alves- Jr., J. L., & Souza, R. (2018). Prognostic relevance of appropriate renal function evaluation in pulmonary arterial hypertension. Journal of heart and lung transplantation, 37( 6), 692-693. doi:10.1016/j.healun.2018.02.005
    • NLM

      Alves- Jr. JL, Souza R. Prognostic relevance of appropriate renal function evaluation in pulmonary arterial hypertension [Internet]. Journal of heart and lung transplantation. 2018 ; 37( 6): 692-693.[citado 2024 nov. 15 ] Available from: https://doi.org/10.1016/j.healun.2018.02.005
    • Vancouver

      Alves- Jr. JL, Souza R. Prognostic relevance of appropriate renal function evaluation in pulmonary arterial hypertension [Internet]. Journal of heart and lung transplantation. 2018 ; 37( 6): 692-693.[citado 2024 nov. 15 ] Available from: https://doi.org/10.1016/j.healun.2018.02.005
  • Source: Chest. Unidade: FM

    Subjects: HIPERTENSÃO PULMONAR, FARMACOTERAPIA

    Acesso à fonteDOIHow to cite
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
    • ABNT

      SOUZA, Rogerio. Building the Future of Trial Design in PAH on Solid Ground. Chest. Amsterdam: Faculdade de Medicina, Universidade de São Paulo. Disponível em: https://doi.org/10.1016/j.chest.2018.01.041. Acesso em: 15 nov. 2024. , 2018
    • APA

      Souza, R. (2018). Building the Future of Trial Design in PAH on Solid Ground. Chest. Amsterdam: Faculdade de Medicina, Universidade de São Paulo. doi:10.1016/j.chest.2018.01.041
    • NLM

      Souza R. Building the Future of Trial Design in PAH on Solid Ground [Internet]. Chest. 2018 ; 153( 5): 1089-1090.[citado 2024 nov. 15 ] Available from: https://doi.org/10.1016/j.chest.2018.01.041
    • Vancouver

      Souza R. Building the Future of Trial Design in PAH on Solid Ground [Internet]. Chest. 2018 ; 153( 5): 1089-1090.[citado 2024 nov. 15 ] Available from: https://doi.org/10.1016/j.chest.2018.01.041
  • Source: Circulation. Unidade: FM

    Subjects: DIABETES MELLITUS, DOENÇAS CARDIOVASCULARES, FÁRMACOS DO SANGUE E SISTEMA HEMATOPOÉTICO

    Acesso à fonteDOIHow to cite
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
    • ABNT

      GIUGLIANO, Robert P. e NICOLAU, Jose Carlos. Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation, v. 137, n. 15, p. 1571-0, 2018Tradução . . Disponível em: https://doi.org/10.1161/CIRCULATIONAHA.117.030950. Acesso em: 15 nov. 2024.
    • APA

      Giugliano, R. P., & Nicolau, J. C. (2018). Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation, 137( 15), 1571-0. doi:10.1161/CIRCULATIONAHA.117.030950
    • NLM

      Giugliano RP, Nicolau JC. Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) [Internet]. Circulation. 2018 ; 137( 15): 1571-0.[citado 2024 nov. 15 ] Available from: https://doi.org/10.1161/CIRCULATIONAHA.117.030950
    • Vancouver

      Giugliano RP, Nicolau JC. Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) [Internet]. Circulation. 2018 ; 137( 15): 1571-0.[citado 2024 nov. 15 ] Available from: https://doi.org/10.1161/CIRCULATIONAHA.117.030950
  • Source: Clinical and experimental rheumatology. Unidade: FM

    Subjects: HIPERTENSÃO PULMONAR, TECIDO CONJUNTIVO, PROGNÓSTICO

    How to cite
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
    • ABNT

      ASSAD, A. P. Luppino et al. Survival of connective tissue disease associated pulmonary arterial hypertension. Clinical and experimental rheumatology. Pisa: Faculdade de Medicina, Universidade de São Paulo. . Acesso em: 15 nov. 2024. , 2018
    • APA

      Assad, A. P. L., Souza, R., Oleas, F. G., Alves Jr., J. L., Fernandes, C. J. C. dos S., & Sampaia-Barros, P. D. (2018). Survival of connective tissue disease associated pulmonary arterial hypertension. Clinical and experimental rheumatology. Pisa: Faculdade de Medicina, Universidade de São Paulo.
    • NLM

      Assad APL, Souza R, Oleas FG, Alves Jr. JL, Fernandes CJC dos S, Sampaia-Barros PD. Survival of connective tissue disease associated pulmonary arterial hypertension. Clinical and experimental rheumatology. 2018 ; 36( 4): S186-S186.[citado 2024 nov. 15 ]
    • Vancouver

      Assad APL, Souza R, Oleas FG, Alves Jr. JL, Fernandes CJC dos S, Sampaia-Barros PD. Survival of connective tissue disease associated pulmonary arterial hypertension. Clinical and experimental rheumatology. 2018 ; 36( 4): S186-S186.[citado 2024 nov. 15 ]
  • Source: Obstetrics and gynecology. Conference titles: 73rd Scientific Congress and Expo of the American-Society-for-Reproductive-Medicine (ASRM). Unidade: FM

    Subjects: ENDOMETRIOSE, HORMÔNIO LIBERADOR DE GONADOTROFINAS

    Acesso à fonteAcesso à fonteDOIHow to cite
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
    • ABNT

      SURREY, Eric et al. Long-term outcomes of elagolix in women with endometriosis. Obstetrics and gynecology, v. 132, n. 1, p. 147-160, 2018Tradução . . Disponível em: https://doi.org/10.1097/AOG.0000000000002675. Acesso em: 15 nov. 2024.
    • APA

      Surrey, E., Taylor, H. S., Giudice, L., Lessey, B. A., Abrao, M. S., Archer, D. F., et al. (2018). Long-term outcomes of elagolix in women with endometriosis. Obstetrics and gynecology, 132( 1), 147-160. doi:10.1097/AOG.0000000000002675
    • NLM

      Surrey E, Taylor HS, Giudice L, Lessey BA, Abrao MS, Archer DF, Diamond MP, Johnson NP, Watts NB, Gallagher JC. Long-term outcomes of elagolix in women with endometriosis [Internet]. Obstetrics and gynecology. 2018 ; 132( 1): 147-160.[citado 2024 nov. 15 ] Available from: https://doi.org/10.1097/AOG.0000000000002675
    • Vancouver

      Surrey E, Taylor HS, Giudice L, Lessey BA, Abrao MS, Archer DF, Diamond MP, Johnson NP, Watts NB, Gallagher JC. Long-term outcomes of elagolix in women with endometriosis [Internet]. Obstetrics and gynecology. 2018 ; 132( 1): 147-160.[citado 2024 nov. 15 ] Available from: https://doi.org/10.1097/AOG.0000000000002675

Digital Library of Intellectual Production of Universidade de São Paulo     2012 - 2024